Please check your internet connection and try again.
# Mylotarg (gemtuzumab ozogamicin)
## Overview
Mylotarg is a chemotherapy agent, specifically a CD33-directed antibody-drug conjugate, used in the treatment of acute myeloid leukemia (AML).
## Primary Indications
* Newly diagnosed CD33-positive AML in adults in combination with other chemotherapy.
* Relapsed or refractory CD33-positive AML in adults.
## Adult Dosing
* **Newly Diagnosed AML (combination):**
* Day 1: 3 mg/m² intravenously.
* Day 4: 3 mg/m² intravenously.
* Day 7: 2 mg/m² intravenously.
* Subsequent cycles (if applicable): 3 mg/m² every 2 weeks.
* **Relapsed or Refractory AML:**
* First cycle: 3 mg/m² intravenously on day 1, 3 mg/m² on day 4, and 2 mg/m² on day 7.
* Second cycle (if criteria met): 3 mg/m² every 2 weeks.
* Maximum cumulative dose: 33 mg/m².
## Pediatric Dosing
Mylotarg is not approved for use in pediatric patients. Safety and efficacy have not been established.
## Dose Adjustments
* **Hepatic Impairment:** Data is limited. Exercise caution. If bilirubin > 1.5 mg/dL or AST > 2.5 times ULN, consider delaying or reducing dose. Consult specialist.
* **Renal Impairment:** Data is limited. Exercise caution.
## Contraindications
* None listed in current prescribing information, but use with extreme caution in patients with pre-existing severe hepatic impairment.
## Adverse Effects
* **Serious:** Hepatotoxicity (including veno-occlusive disease/sinusoidal obstruction syndrome), myelosuppression (neutropenia, thrombocytopenia, anemia), infusion-related reactions, tumor lysis syndrome, gastrointestinal toxicity (nausea, vomiting, mucositis, diarrhea), hyperbilirubinemia.
* **Common:** Fever, nausea, vomiting, diarrhea, constipation, abdominal pain, mucositis, headache, fatigue, rash, cough, dyspnea, peripheral edema, hypokalemia.
## Key Drug Interactions
* No specific drug interactions identified in prescribing information, but caution with other myelosuppressive agents.
## Monitoring
* **Baseline and regular monitoring:** Complete blood counts with differential and platelet count, liver function tests (bilirubin, AST, ALT), renal function tests (creatinine).
* **During infusion:** Vital signs for infusion-related reactions.
* **Post-infusion:** Monitor closely for signs and symptoms of hepatotoxicity, myelosuppression, and tumor lysis syndrome.
## Clinical Pearls
* Mylotarg is associated with a significant risk of hepatotoxicity, particularly veno-occlusive disease/sinusoidal obstruction syndrome, which can be fatal. Patients with pre-existing hepatic impairment are at higher risk.
* Administer only under the supervision of a physician experienced in the treatment of AML.
* Premedication to prevent infusion reactions may be considered.
* Discontinue treatment if signs of severe hepatotoxicity or unacceptable toxicity occur.
* Ensure adequate hydration and electrolyte management, especially in patients at risk for tumor lysis syndrome.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and individual patient factors before making clinical decisions. Local protocols may dictate specific dosing or management strategies.*
